Lee Ainslie Catalent, Inc. Transaction History

Maverick Capital LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$45.44 - $74.26 $15.7 Million - $25.7 Million	-345,689 Reduced 24.66%	1,055,960 $69.4 Million
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $58 Million - $114 Million	1,401,649 New	1,401,649 $63.1 Million
Q1 2021 May 17, 2021	SELL	$101.51 - $125.27 $86,689 - $106,980	-854 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$85.88 - $105.36 $73,341 - $89,977	854 New	854 $89,000

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.